美白祛斑凝乳的研制及临床观察

目的:研制具有美白祛斑功能的新型制剂并进行临床观察研究。方法:改进凝胶制备工艺并加入药物功能性添加剂而制得凝乳;凝乳治疗黄褐斑30例并以氢醌霜为对照,比较性状和功能。结果:凝乳制剂保留了凝胶的优点并有美白祛斑功效,治疗黄褐斑外用一月后总有效率100%,显效率70%(21/30)。与对照组比较都有提高(P<0.05)。结论:美白祛斑凝乳是具有明显治疗护肤功能的新型外用制剂。     

氨甲环酸:一种治疗黄褐斑的重要辅助药物

综述氨甲环酸老药新用治疗黄褐斑的临床疗效及安全性,探讨其通过抑制纤溶酶原活化系统以防止黑色素细胞在紫外线、激素、受伤角质细胞等作用下的增长的作用机制,并对氨甲环酸治疗方法与现有黄褐斑治疗方法进行比较。越来越多的临床研究表明,口服和(或)局部给予氨甲环酸治疗黄褐斑疗效良好,不良反应少,可单独或联合其他药物或方法进行治疗。     

Development and validation of a health-related quality of life instrument for women with melasma

BACKGROUND: Melasma can have significant emotional and psychological effects on those affected with the condition. In the past, the impact of melasma on health-related quality of life (HRQoL) has been assessed using general measures of skin disease that equally weigh both the physical and psychosocial distress arising from the presence of a dermatological condition. OBJECTIVES: Our purpose was to develop and validate a disease-specific HRQoL instrument to identify the areas of the patient's life most impaired by melasma as well as the effects of the condition on their level of functioning in correlation with disease severity: the Melasma Quality of Life scale (MELASQOL). PATIENTS AND METHODS: A random sample of 102 women identified by an investigator as having melasma were evaluated by the investigator using the Melasma Area and Severity Index (MASI). The patients were then anonymously surveyed with the SKINDEX-16, the Fear of Negative Evaluation scale, the Dermatology Life Quality Index (DLQI), a skin discoloration evaluation questionnaire, and a measure of perceived life quality difference without melasma. The 10-item MELASQOL scale was devised from the comprehensive HRQoL assessment battery. RESULTS: The psychometric properties of the MELASQOL were comparable with the properties of the DLQI and the SKINDEX-16. The MELASQOL scores were highly correlated with the other HRQoL measures. The discriminatory ability of the MELASQOL is superior to the SKINDEX-16 and the DLQI for melasma. The three life domains most adversely affected by melasma (social life, recreation/leisure and emotional well-being) were highlighted by this instrument. These were the same three areas of life that patients believed would improve the most if they no longer were affected by the disease. CONCLUSIONS: The MELASQOL can be used to evaluate objectively the effect of melasma on a patient's HRQoL. The high correlation with the DLQI, the SKINDEX-16 and the skin discoloration questionnaire suggests that the new scale is a valid instrument, which can be used to monitor the level of impairment individuals suffer due to their melasma. The MELASQOL scores can help guide treatment methods as well as track the improvement of patients' HRQoL.     

L-抗坏血酸-2-磷酸酯镁霜外用治疗黄褐斑临床疗效观察

目的:观察L-抗坏血酸-2-磷酸酯镁(VC-PMG)霜外用治疗黄褐斑的疗效及安全性.方法:外用10%VC-PMG霜治疗25例黄褐斑患者,并用Micmskin Ⅱ多功能偏振光皮肤镜图像分析系统对治疗前、后黄褐斑皮损进行客观测量及评价.结果:经10%VC-PMG霜外用治疗各型黄褐斑16周后,平均有效率为20%,其中单一蝶形皮损效果最佳,有效率为44.4%,同一患者治疗前后对色素斑L*、a*、b*值检测结果显示差异有统计学意义(P<0.05).在临床治疗观察的整个过程中未见明显不良反应发生.结论:局部外用10%VC-PMG霜可以减少黄褐斑患者皮损部位的黑素含量、毛细血管扩张程度,以及减轻黄色素和脂色素以改善色素斑,达到治疗黄褐斑的目的.     

积雪苷霜软膏治疗黄褐斑随机、双盲、自身对照试验研究

目的：评估积雪苷霜软膏R治疗黄褐斑的临床疗效及安全性。方法：采用12周随机、双盲、自身对照试验,受试者左右两侧面部黄褐斑区域随机使用积雪苷霜软膏R与不含积雪草总苷成分的安慰剂,观察色斑改善程度。通过第0周、第4周、第8周、第12周研究者盲法评价黄褐斑面积及严重程度指数（MASI）、受试者盲法自评、仪器测量三个方面评价比较用药侧与安慰剂侧黄褐斑的改善情况。结果：共纳入符合要求的研究对象36例全部按期完成,在试验结束揭盲后统计,受试者的治疗侧MASI指数下降45%,结合受试者对疗效的自我评估、颜色定量测量及拍照,治疗侧疗效明显优于安慰剂侧。结论：本研究结果显示积雪苷霜软膏R治疗黄褐斑皮肤耐受性良好,临床疗效明显优于安慰剂。     

中药周期性阶段疗法治疗肝肾阴虚型黄褐斑疗效观察

目的：观察中药周期性阶段疗法治疗黄褐斑的临床疗效。方法：将123例患者随机分为两组,治疗组62例,采用月经后服用补精血颗粒与月经前及经期服用理气养血活血颗粒的周期性阶段治疗;对照组61例,采用补精活血颗粒的持续性给药治疗,2个疗程后判定临床疗效。结果：总有效率治疗组为95.08%,对照组为93.22%,两组比较差异无统计学意义（P〉0.05）。结论：两组临床疗效相当,均能有效治疗黄褐斑。